Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

Neurology

Volumn 72, Issue 15, 2009, Pages 1322-1329

  Teunissen, C E ^a   Iacobaeus, E ^d   Khademi, M ^d   Brundin, L ^d   Norgren, N ^e   Koel Simmelink, M J A ^a   Schepens, M ^a   Bouwman, F ^b   Twaalfhoven, H A M ^c   Blom, H J ^c   Jakobs, C ^c   Dijkstra, C D ^a  

^a Department of Molecular Cell Biology and Immunology   (Netherlands)

^b Department of Neurology ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UmanDiagnostics AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; N ACETYLASPARTIC ACID; TAU PROTEIN; AMINO ACID; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE; NEUROFILAMENT PROTEIN;

ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; DISEASE COURSE; HEAVY CHAIN; HUMAN; INFLAMMATORY DISEASE; LIGHT CHAIN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROFILAMENT; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; SYNDROME; COHORT ANALYSIS; NERVE DEGENERATION; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

AMINO ACIDS; ASPARTIC ACID; AXONS; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE DEGENERATION; NEUROFILAMENT PROTEINS; TAU PROTEINS;

EID: 65349157666     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a0fe3f     Document Type: Article

References (28)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
2. Lisak RP. Neurodegeneration in multiple sclerosis: defining the problem. Neurology 2007;68(22 suppl 3):S5-S12.
3. Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007;13:490-501.
4. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol 2007;17:230-242.
5. Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007;13:1483-1489.
6. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 2006;281:31950-31962.
7. Teunissen CE, Dijkstra CD, Polman CH. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41.
8. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004;63:1586-1590.
9. Petzold A, Eikelenboom MI, Keir G, et al. The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 2006;12:325-328.
10. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81:89-131.
11. Jasperse B, Jakobs C, Eikelenboom MJ, et al. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol 2007;254:631-637.
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
14. Svenungsson E, Andersson M, Brundin L, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001;60:372-379.
15. Jakobs C, ten Brink HJ, Langelaar SA, et al. Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease. J Inherit Metab Dis 1991;14:653-660.
16. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987: 25-31.
17. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G. Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 2003;138:45-48.
18. Beutler H-O, Michal G. L-Glutamate: determination with glutamate dehydrogenase, diaphorase, and tetrazolium salts. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press; 1974:1708-1713.
19. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003;21:79-96.
20. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
21. Guimaraes I, Cardoso MI, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006;12:354-356.
22. Brettschneider J, Maier M, Arda S, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005;11:261-265.
23. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12:143-148.
24. Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007;115:325-330.
25. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-198.
26. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006;59:478-489.
27. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901.
28. Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers 2006;22:187-196.